Dr. Mona Kamal Saadeldin | Pharmacology | Best Researcher Award Posted on 31/07/202431/07/2024 by sciencefather Dr. Mona Kamal Saadeldin | Pharmacology | Best Researcher Award Dr. Mona Kamal Saadeldin, Researcher, University of Wisconsin Madison, United States 🌟 Dr. Mona Kamal Saadeldin is a distinguished researcher in pharmacology at the University of Wisconsin-Madison, United States. Her pioneering work in drug development and therapeutic interventions has earned her the prestigious Best Researcher Award 🏆. With a passion for advancing medical science, Dr. Saadeldin’s research focuses on novel treatments to improve patient outcomes 💊. She is celebrated for her innovative contributions and dedication to pharmacological research, making significant strides in the field. Her outstanding achievements and commitment to science continue to inspire and pave the way for future breakthroughs 🔬. PROFILE 📝 Googlescholar EDUCATION 🎓 🎓 Dr. Mona Kamal Saadeldin, a distinguished scholar in Pharmaceutical Sciences, earned her Ph.D. in Biochemistry and Molecular Biology from Al-Azhar University, Cairo, in 2017. She holds two M.Sc. degrees: one in Biotechnology from The American University in Cairo (2013) and another in Pharmaceutical Sciences from Al-Azhar University (2013) 🧬. Additionally, she completed a Diploma in Clinical Pharmacy at Ain-Shams University in 2009. Her academic journey began with a B.Sc. in Pharmaceutical Sciences from Ain-Shams University in 2006 🧪. Dr. Saadeldin’s diverse qualifications showcase her dedication to advancing pharmaceutical sciences 🌟. RESEARCH EXPERIENCE 🔬 🌟 Dr. Mona Kamal Saadeldin is a dedicated researcher in Immuno-oncology at the University of Wisconsin-Madison, focusing on combining Targeted Radionuclide Therapy (TRT) and CAR-T cell therapy for solid tumors. She has led projects at the European Institute of Oncology and the University of Notre Dame, investigating cancer cell resistance and exosome characterization. 🧬💉 In Egypt, Dr. Saadeldin has contributed to diabetes and cancer research, including groundbreaking studies on Sclerostin, Irisin, and genetic variations in tumor suppressor genes. 📚🧪 As an educator, she has supervised and trained students, fostering future scientific innovation. 🌿👩🏫 CONFERENCE POSTER PRESENTATIONS 📊 Dr. Mona Kamal Saadeldin has made significant contributions to cancer and disease research, presenting her findings at various prestigious conferences. Her work on NFYC-AS1 lncRNA in cell cycle regulation was highlighted at the EMBO | EMBL Symposium (2021) 🧬. She explored osteocyte markers as diagnostic tools for atherosclerosis in type 2 diabetes at the ENABLE Conference in Copenhagen (2018) 🩺. Additionally, Dr. Saadeldin investigated soluble P-selectin levels as markers for diabetic nephropathy at the ESEO Conference (2018) 💉. Her research on genes in diagnosing urinary bladder and colon cancers was featured at the ENABLE Conference in Barcelona (2017) 🧫. PROFESSIONAL MEMBERSHIPS 🤝 🎓 Dr. Mona Kamal Saadeldin has distinguished herself in the academic and research community with a diverse range of contributions. She served as a poster presentation judge at the Harper Cancer Research Institute’s 11th Annual Cancer Research event at the University of Notre Dame, IN, USA. 📚 Dr. Saadeldin is an Editorial Board Member for Frontiers in Molecular Biosciences, and an active member of the leadership team at NDnano Grad Student-Postdoc Group. 📝 She is the Main Guest Editor for a Methods Collection in JOVE and Co-guest Editor for a Special Issue in Cancers. Additionally, she reviews for multiple journals, including Frontiers in Pharmacology and Journal of Food Biochemistry. 🌟 AWARDS 🏆 🎓 Dr. Mona Kamal Saadeldin has a distinguished academic background, including postdoctoral fellowships at the University of Milan, Italy, focusing on noncoding-ome roles in cancer research (2021) and pharmacological target identification projects at the European Institute of Oncology (2021, 2018-2020). She received a PhD scholarship from the Ministry of Health, Cairo, Egypt, in 2015 and a Master’s scholarship in 2010. Additionally, Dr. Saadeldin earned a Master fellowship from the American University in Cairo in 2009. 🌟🔬 Her work contributes significantly to oncology and neurological research. 🧬💼 PUBLICATION TOP NOTES 📚 Anti-diabetic effects of fenugreek (Trigonella foenum-graecum): A comparison between oral and intraperitoneal administration – an animal study Dendritic cell vaccine immunotherapy; the beginning of the end of cancer and COVID-19. A hypothesis Serum sclerostin and irisin as predictive markers for atherosclerosis in Egyptian type II diabetic female patients: A case control study Effects of Turmeric (Curcuma longa) Extract in streptozocin‐induced diabetic model Tuning mTORC1 activity dictates the response of acute myeloid leukemia to LSD1 inhibition Tuning mTORC1 activity dictates the response of acute myeloid leukemia to LSD1 inhibition A critical review of chloroquine and hydroxychloroquine as potential adjuvant agents for treating people with cancer Preclinical models of breast cancer: Two-way shuttles for immune checkpoint inhibitors from and to patient bedside Thermal stability of a mercuric reductase from the Red Sea Atlantis II hot brine environment as analyzed by site-directed mutagenesis Indolin-2-one derivatives as selective Aurora B kinase inhibitors targeting breast cancer